{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:49Z","timestamp":1786997929906,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urolonc.2025.07.025","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:55:28Z","timestamp":1755741328000},"page":"599-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular classification of nonurothelial histologic subtypes of bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Michelle I.","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo Tony","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora J.","family":"Grutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Matoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0002","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin Med Insights: Pathol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.07.025_bib0003","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/srep10957","article-title":"Biological determinants of bladder cancer gene expression subtypes","volume":"5","author":"Aine","year":"2015","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0006","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.urolonc.2025.07.025_bib0008","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.025_bib0009","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sjodahl","year":"2013","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.07.025_bib0011","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.025_bib0013","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0014","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.urolonc.2025.07.025_bib0015","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1158\/1078-0432.CCR-12-1807","article-title":"Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis","volume":"18","author":"Hurst","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0017","doi-asserted-by":"crossref","first-page":"18.e15","DOI":"10.1016\/j.urolonc.2014.10.001","article-title":"Contemporary bladder cancer: variant histology may be a significant driver of disease","volume":"33","author":"Monn","year":"2015","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0018","doi-asserted-by":"crossref","first-page":"20.e23","DOI":"10.1016\/j.urolonc.2014.06.012","article-title":"Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology","volume":"33","author":"Rice","year":"2015","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0019","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.urolonc.2025.07.025_bib0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"7492","key":"10.1016\/j.urolonc.2025.07.025_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.025_bib0022","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0023","first-page":"37","article-title":"Effect of thyroid hormone on the contents of NOS and CO in the penile corpus cavernosum of rats]","volume":"15","author":"Hu","year":"2009","journal-title":"Zhonghua Nan Ke Xue"},{"issue":"7","key":"10.1016\/j.urolonc.2025.07.025_bib0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.07.025_bib0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/00000478-199412000-00005","article-title":"Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma","volume":"18","author":"Amin","year":"1994","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0026","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.07.025_bib0027","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3109\/00313025.2010.522173","article-title":"Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases","volume":"42","author":"Comperat","year":"2010","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0028","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/CS20130580","article-title":"miR-296\/scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo","volume":"127","author":"Savi","year":"2014","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.025_bib0029","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1158\/1078-0432.CCR-10-0993","article-title":"Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion","volume":"17","author":"Wei","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0030","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.5858\/2004-128-e8-COTUBF","article-title":"Carcinosarcoma of the urinary bladder following cyclophosphamide therapy: evidence for monoclonal origin and chromosome 9p allelic loss","volume":"128","author":"Mukhopadhyay","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/454792","article-title":"Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases","volume":"2010","author":"Wang","year":"2010","journal-title":"Sarcoma"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0032","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/j.clgc.2019.05.019","article-title":"Genomic analysis and treatment response of a bladder urothelial carcinoma with sarcomatoid variant histology","volume":"17","author":"Narayan","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0033","series-title":"Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer","first-page":"826","author":"Genitsch","year":"2019"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0034","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/path.6060","article-title":"Progression-associated molecular changes in basal\/squamous and sarcomatoid bladder carcinogenesis","volume":"259","author":"Fontugne","year":"2023","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0035","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00018-017-2717-4","article-title":"CREBBP and p300 lysine acetyl transferases in the DNA damage response","volume":"75","author":"Dutto","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0037","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.humpath.2010.11.011","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series","volume":"42","author":"Raspollini","year":"2011","journal-title":"Human Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.025_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.urolonc.2016.12.006","article-title":"Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy","volume":"35","author":"Moschini","year":"2017","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0039","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinomas: a chemo-sensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"},{"issue":"25","key":"10.1016\/j.urolonc.2025.07.025_bib0040","first-page":"210","article-title":"Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma","volume":"S0302-2838","author":"Chu","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.025_bib0041","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-017-2190-3","article-title":"FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma","volume":"471","author":"Warrick","year":"2017","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0042","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0043","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105788","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: a single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry","volume":"158","author":"Korentzelos","year":"2025","journal-title":"Human Pathol"},{"issue":"13","key":"10.1016\/j.urolonc.2025.07.025_bib0045","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-18-3558","article-title":"Molecular characterization of neuroendocrine-like bladder cancer","volume":"25","author":"Batista da Costa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0046","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1464-410X.2003.04893.x","article-title":"Small cell carcinoma of the bladder","volume":"94","author":"Sved","year":"2004","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0047","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2559.2004.01980.x","article-title":"Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases","volume":"46","author":"Abrahams","year":"2005","journal-title":"Histopathology"},{"issue":"23","key":"10.1016\/j.urolonc.2025.07.025_bib0048","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1002\/cncr.26197","article-title":"A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends","volume":"117","author":"Koay","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0049","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cncr.20456","article-title":"Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients","volume":"101","author":"Cheng","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.025_bib0050","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/j.clgc.2016.09.005","article-title":"Small-cell carcinoma of the bladder: 20-year single-institution retrospective review","volume":"15","author":"Jung","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2025.07.025_bib0051","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/0956462414533099","article-title":"2013 European guideline for the management of balanoposthitis","volume":"25","author":"Edwards","year":"2014","journal-title":"Int J STD AIDS"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0052","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/iju.12038","article-title":"Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder","volume":"20","author":"Meijer","year":"2013","journal-title":"Int J Urol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.07.025_bib0053","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1038\/s41388-018-0192-5","article-title":"Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics","volume":"37","author":"Shen","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0054","doi-asserted-by":"crossref","unstructured":"Feng M., Matoso A., Epstein G., et al. Identification of lineage-specific transcriptional factor\u2013defined molecular subtypes in small cell bladder cancer. Eur Urol. doi:10.1016\/j.eururo.2023.05.023","DOI":"10.1016\/j.eururo.2023.05.023"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.025_bib0055","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5\u2013SN38 antibody\u2013drug conjugate in neuroendocrine prostate cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0056","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2017.33","article-title":"Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma","volume":"30","author":"Roy","year":"2017","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.07.025_bib0057","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00383-014-3593-8","article-title":"The great divide: septation and malformation of the cloaca, and its implications for surgeons","volume":"30","author":"Gupta","year":"2014","journal-title":"Pediatr Surg Int"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0058","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.humpath.2020.01.004","article-title":"The applicability and utility of immunohistochemical biomarkers in bladder pathology","volume":"98","author":"Akgul","year":"2020","journal-title":"Human Pathol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0059","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.eururo.2016.04.037","article-title":"Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition","volume":"70","author":"Collazo-Lorduy","year":"2016","journal-title":"Eur Urol"},{"issue":"51","key":"10.1016\/j.urolonc.2025.07.025_bib0060","doi-asserted-by":"crossref","first-page":"S530","DOI":"10.1016\/S0959-8049(16)31467-8","article-title":"2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma","volume":"3","author":"Jordan","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2025.07.025_bib0061","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.31547","article-title":"Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas","volume":"143","author":"Reis","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.07.025_bib0062","first-page":"1","article-title":"Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype","author":"Kardos","year":"2017","journal-title":"JCO Precision Oncol"},{"issue":"18","key":"10.1016\/j.urolonc.2025.07.025_bib0063","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.3390\/cancers14184411","article-title":"Expression of nectin-4 in variant histologies of bladder cancer and its prognostic value\u2014need for biomarker testing in high-risk patients?","volume":"14","author":"Rodler","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.025_bib0064","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1464-410X.2005.05327.x","article-title":"Non-transitional cell bladder carcinomas","volume":"95","author":"Manunta","year":"2005","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.025_bib0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.eururo.2018.06.047","article-title":"Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications","volume":"74","author":"Hovelson","year":"2018","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.07.025_bib0066","first-page":"8143","article-title":"Comparison of structural genetics of non-schistosoma-associated squamous cell carcinoma of the urinary bladder","volume":"8","author":"Molitor","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"10061","key":"10.1016\/j.urolonc.2025.07.025_bib0067","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.025_bib0068","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/00005392-199805000-00023","article-title":"Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases","volume":"159","author":"Lopez-Beltran","year":"1998","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.025_bib0069","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.urolonc.2025.07.025_bib0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1755-8794-5-40","article-title":"miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer","volume":"5","author":"Nordentoft","year":"2012","journal-title":"BMC Med Genomics"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0071","doi-asserted-by":"crossref","first-page":"E325","DOI":"10.1111\/j.1464-410X.2012.11751.x","article-title":"Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer","volume":"111","author":"Meeks","year":"2013","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2025.07.025_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","author":"Jasim","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"7637","key":"10.1016\/j.urolonc.2025.07.025_bib0073","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.urolonc.2025.07.025_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100424","article-title":"Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2","volume":"37","author":"Posada","year":"2024","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.07.025_bib0075","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Brit J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.07.025_bib0076","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","article-title":"Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile","volume":"4","author":"Hoffman-Censits","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.025_bib0077","first-page":"230","article-title":"Two cases of aggressive sarcomatoid urothelial carcinoma reveal potential molecular targets","volume":"5","author":"Hertz","year":"2021","journal-title":"Eur J Med Case Rep"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:12:55Z","timestamp":1759299175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1078143925002777"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.025","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular classification of nonurothelial histologic subtypes of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}